- Join Us
- About A2C
- About CRI
- Why Immunotherapy
Join us on June 25, 2016, for an inspiring 1-day cycling event through the Lower Hudson Valley's breathtaking landscape.
Sharon was shocked when she was diagnosed with stage 4 melanoma at age 22. She joined a clinical trial of the immunotherapy ipilimumab (Yervoy), and has been in remission ever since.
Read Sharon's Story
By age 20, Milton had already battled leukemia three times. His doctor then recommended he enter an immunotherapy clinical trial using CAR T cell therapy.
Read Milton's Story
When computer professional Don, 61, was facing a grim prognosis from chemo-resistant lung cancer, he did what came naturally: he took to Google to research his options and came across articles on PD-1 immunotherapy.
Read Don's Story
|Top 5 Teams||Donations Raised|
|1 | Team CD&R||$58,505|
|2 | Team Young Philanthropists||$26,708|
|3 | MUFG||$24,231|
|4 | Coatue||$20,915|
|5 | Goldman Sachs||$17,380|